Can’t find what you’re looking for? Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Order Online! Now! Get your $50 coupon for online order. 
Order Online! Now! Get your $50 coupon for online order.
Get your basement membrane extract free sample to test now! Get your basement membrane extract free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| FG4-H5253 | Human | Human FGF R4 / CD334 Protein, Fc Tag (MALS & SPR verified) |  |
|
|
| FG4-M52Ha | Mouse | Mouse FGF R4 / CD334 Protein, His Tag |  |
|
|
| FG4-H5228 | Human | Human FGF R4 / CD334 Protein, His Tag |  |
|
Human FGF R4, Fc Tag (Cat. No. FG4-H5253) immobilized on CM5 Chip can bind Human FGF-4 Protein, His Tag (Cat. No. FG4-H51H3) with an affinity constant of 1.48 μM as determined in a SPR assay (Biacore 8K) (QC tested).
The purity of Human FGF R4, Fc Tag (Cat. No. FG4-H5253) is more than 90% and the molecular weight of this protein is around 145-175 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Erdafitinib | 890E37NHMV; JNJ-42756493; G-024; JNJ-493 | Approved | Astex Pharmaceuticals Inc | Balversa | United States | Carcinoma, Transitional Cell | Janssen Biotech Inc | 2019-04-12 | Carcinoma, Squamous Cell; Neuroblastoma; Breast Neoplasms; Sarcoma; Urologic Neoplasms; Hepatic Insufficiency; Histiocytic Sarcoma; Bile Duct Neoplasms; Neoplasms, Neuroepithelial; Glioma; Sarcoma, Ewing; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasms, Germ Cell and Embryonal; Adenocarcinoma; Neuroectodermal Tumors, Primitive, Peripheral; Xanthogranuloma, Juvenile; Hepatoblastoma; Ependymoma; Medulloblastoma; Hematologic Neoplasms; Rhabdomyosarcoma; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Rhabdoid Tumor; Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Wilms Tumor; Multiple Myeloma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Osteosarcoma; Histiocytosis, Langerhans-Cell | Details |
| Futibatinib | TAS-120 | Approved | Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd | LYTGOBI | United States | Cholangiocarcinoma | Taiho Oncology Inc | 2022-09-30 | Solid tumours; Bone Marrow Neoplasms; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Sarcoma; Lymphoma; Carcinoma, Non-Small-Cell Lung | Details |
| Lenvatinib Mesylate | ER-203492-00; E-7080; MK-7902 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Liver Diseases; Paraganglioma; Neoplasm Metastasis; Thyroid Cancer, Papillary; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Osteosarcoma; Cholangiocarcinoma; Breast Neoplasms; Solid tumours; Neuroendocrine Tumors; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Kidney Diseases; Neoplasms; Adenocarcinoma of Lung; Thyroid Carcinoma, Anaplastic; Pheochromocytoma; Renal Insufficiency; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| H3B-6527 | H3B-6527 | Phase 1 Clinical | H3 Biomedicine Inc | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
| ZSP-1241 | ZSP-1241 | Phase 1 Clinical | Guangdong Zhongsheng Pharmaceutical Co Ltd, Wuxi Apptec Co Ltd | Liver Neoplasms; Biliary Tract Neoplasms; Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular | Details |
| ICP-105 | ICP-105 | Phase 1 Clinical | Nanjing Tianyin Jianhua Pharmaceutical Technology Co Ltd, Beijing Tiancheng Pharmaceutical Technology Co Ltd, Beijing Innocare Pharma Tech Co Ltd | Liver Neoplasms; Solid tumours | Details |
| SYHX-2005 | SYHX-2005; SYHX2005 | Phase 1 Clinical | Cspc Ouyi Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| ABSK-011 | ABSK-011 | Phase 2 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours; Liver Neoplasms; Carcinoma, Hepatocellular | Details |
| JAB-6343 | Phase 1 Clinical | Solid tumours | Details | ||
| Roblitinib | FGF-401; NVP-FGF401 | Phase 2 Clinical | Novartis Pharma Ag | Solid tumours; Neoplasms; Carcinoma, Hepatocellular | Details |
| Aldafermin | M-70; NGM-282 | Phase 2 Clinical | Ngm Biopharmaceuticals Inc | Liver Cirrhosis, Biliary; Constipation; Non-alcoholic Fatty Liver Disease; Renal Insufficiency; Irritable Bowel Syndrome; Fibrosis; Cholangitis, Sclerosing; Diarrhea; Hepatic Insufficiency; Diabetes Mellitus; Malabsorption Syndromes | Details |
| BPI-43487 | BPI-43487 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Biliary Tract Neoplasms; Solid tumours; Carcinoma, Hepatocellular | Details |
| EVER-4010001 | EVER-4010001 | Phase 2 Clinical | EverNov Medicines (Zhuhai Hengqin) Co Ltd | Solid tumours | Details |
| Fisogatinib | BLU-554; CS-3008 | Phase 2 Clinical | Blueprint Medicines Corp | Carcinoma, Hepatocellular | Details |
| HS-10340 | HS-10340 | Phase 1 Clinical | Changzhou Hengbang Pharmaceutical Co Ltd, Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd | Solid tumours | Details |
| SY-4798 | Phase 1 Clinical | Shouyao Holding (Beijing) Co Ltd | Solid tumours | Details | |
| HS-236 | HS-236 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Solid tumours | Details |
| SC-0011 | SC-0011 | Phase 1 Clinical | Shijiazhuang Zhikang Hongren New Drug Development Co Ltd | Solid tumours | Details |
| Gunagratinib | ICP-192 | Phase 2 Clinical | Beijing Tiancheng Pharmaceutical Technology Co Ltd | Solid tumours; Head and Neck Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms | Details |
| Rogaratinib | BAY-1163877 | Phase 2 Clinical | Bayer AG | Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.
A-Z
